Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor and remains a therapeutic challenge: even after multimodal therapy, median survival of patients is only 15 months. Dendritic cell vaccination (DCV) is an active immunotherapy that aims at inducing an antitumoral immune response. Numerous DCV trials have been performed, vaccinating hundreds of GBM patients and confirming feasibility and safety. Many of these studies reported induction of an antitumoral immune response and indicated improved survival after DCV. However, two controlled randomized trials failed to detect a survival benefit. This raises the question of whether the promising concept of DCV may not hold true or whether we are not yet realizing the full potential of this therapeutic approach. Here, we discuss the results of recent vaccination trials, relevant parameters of the vaccines themselves and of their application, and possible synergies between DCV and other therapeutic approaches targeting the immunosuppressive microenvironment of GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“Based on gene expression signatures, GBM can be further subdivided into mesenchymal, proneural, neural and classical subtypes (2).”
BackgroundMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“4 months), results that were confirmed in a second trial (18); and Provenge/ sipuleucel-T was the first (and so far only) DC vaccine approved by the U.”
ResultMacrophage plasticity, polarization, and function in health and disease
Shapouri‐Moghaddam, A., Mohammadian, S., Vazini, H., Taghadosi, M., Esmaeili, S., Mardani, F., Seifi, B., Mohammadi, A., Afshari, J. T., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26429 · Cited by 4,930
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 2×
“An association of survival and the extent of resection, which by itself is predictive for better survival (89), has also been reported for DCV (78), and a state of minimal residual disease has been indicated to be beneficial for vaccination therapy (44, 48, 65, 78).”
BackgroundM-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Stein, M., Keshav, S., Harris, N., & Gordon, S. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.287 · Cited by 1,960
The many faces of macrophage activation
Mosser, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602325 · Cited by 1,902
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
The role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
CCR7 and its ligands: balancing immunity and tolerance
Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Koch, M. A., Tucker-Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B., & Campbell, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1731 · Cited by 1,258
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011
CD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner
Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A., & Rudensky, A. Y. (2009) · Science · doi:10.1126/science.1172702 · Cited by 1,000
Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses
Zheng, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J. M., Chu, T.-T., Corcoran, L., Treuting, P., Klein, U., & Rudensky, A. Y. (2009) · Nature · doi:10.1038/nature07674 · Cited by 958
The role of macrophage phenotype in vascularization of tissue engineering scaffolds
Spiller, K. L., Anfang, R. R., Spiller, K. J., Ng, J., Nakazawa, K. R., Daulton, J. W., & Vunjak-Novakovic, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.012 · Cited by 948
Human memory T cells: generation, compartmentalization and homeostasis
Farber, D. L., Yudanin, N. A., & Restifo, N. P. (2014) · Nature Reviews Immunology · doi:10.1038/nri3567 · Cited by 897
Tumor-associated macrophages: from basic research to clinical application
Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847
Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Pereira da Costa, M., & Reis e Sousa, C. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-061020-053707 · Cited by 757 · cited 1×
“Dendritic cells (DC) are professional antigen-presenting cells, which are key to the development of T-cell responses (11, 12).”
BackgroundThe brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Liang, B., Workman, C., Lee, J., Chew, C., Dale, B. M., Colonna, L., Flores, M., Li, N., Schweighoffer, E., Greenberg, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5916 · Cited by 566
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Dendritic Cell Regulation of T Helper Cells
Yin, X., Chen, S., & Eisenbarth, S. C. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-025146 · Cited by 447
Origin of microglia: current concepts and past controversies
Ginhoux, F., & Prinz, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020537 · Cited by 446
Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T. (2019) · Science · doi:10.1126/science.aav7062 · Cited by 386
The Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
Savage, P. A., Klawon, D. E. J., & Miller, C. H. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100219-020937 · Cited by 321
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
Garg, A. D., Vandenberk, L., Koks, C., Verschuere, T., Boon, L., Van Gool, S. W., & Agostinis, P. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0105 · Cited by 270
Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237
Lolmede, K., Campana, L., Vezzoli, M., Bosurgi, L., Tonlorenzi, R., Clementi, E., Bianchi, M. E., Cossu, G., Manfredi, A. A., Brunelli, S., et al. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0908579 · Cited by 216
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
Dutoit, V., Herold-Mende, C., Hilf, N., Schoor, O., Beckhove, P., Bucher, J., Dorsch, K., Flohr, S., Fritsche, J., Lewandrowski, P., et al. (2012) · Brain · doi:10.1093/brain/aws042 · Cited by 201
Jürgens, B., Hainz, U., Fuchs, D., Felzmann, T., & Heitger, A. (2009) · Blood · doi:10.1182/blood-2008-12-195073 · Cited by 176
Caruso, D. A., Orme, L. M., Neale, A. M., Radcliff, F. J., Amor, G. M., Maixner, W., Downie, P., Hassall, T. E., Tang, M. L. K., & Ashley, D. M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000668 · Cited by 165 · cited 1×
“Patients included mainly adults, but also children and adolescents (34, 38, 39, 41, 48, 52, 61, 64, 65, 69, 78), and the age of vaccinated patients varied between 1 and 80 years.”
BackgroundImmune checkpoint inhibitor toxicities
Marin-Acevedo, J. A., Chirila, R. M., & Dronca, R. S. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.012 · Cited by 160
Michels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., & Shurin, M. R. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.642418 · Cited by 158
Cited by
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Glioblastoma Microenvironment and Cellular Interactions
Crivii, C.-B., Boșca, A. B., Melincovici, C. S., Constantin, A.-M., Mărginean, M., Dronca, E., Suflețel, R., Gonciar, D., Bungărdean, M., & Șovrea, A. (2022) · Cancers · doi:10.3390/cancers14041092 · Cited by 81
Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
Frederico, S. C., Darling, C., Bielanin, J. P., Dubinsky, A. C., Zhang, X., Hadjipanayis, C. G., & Kohanbash, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1057567 · Cited by 15
Metadata
- Authors
- Datsi, A., & Sorg, R. V.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-11-02
- Volume
- 12
- Pages
- 770390-770390
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3208865630
- Cited by
- 100
- References
- 55
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.